表皮生长因子受体和RAS/MAPK信号通路相关蛋白在肺腺癌中的表达及临床意义

Expression of EGFR and RAS/MAPK signal pathway-related proteins and their significance in lung adenocarcinoma

目的探讨RAS/MAPK信号传导通路与肺腺癌临床病理特征以及预后的关系。方法采用免疫组织化学法和蛋白印迹法(Western blot)检测23例肺腺癌患者及9例非癌肺疾病患者组织标本中表皮生长因子受体(EGFR)、磷酸化信号转导转录因子1(pSTAT1)和磷酸化RAS/MAPK信号通路活化蛋白(pERK1/2)的表达。结果EGFR和活化蛋白pERK1/2在23例肺腺癌患者中表达率分别为73.9%(17/23)和65.2%(15/23),半定量分析显示肺腺癌组pERK1/2蛋白水平显著高于非癌组(1.303±0.656)%vs(0.262±0.213)%,且pERK1/2表达与肺腺癌患者的病理分级程度和有无淋巴结转移之间差异有统计学意义(χ2=12.049和6.626,均P<0.05),肺癌不同TNM分期间pERK1/2表达差异无统计学意义;STAT1在23例肺腺癌患者肺组织中阳性表达率为30.4%,与非癌组比较差异无统计学意义。结论 RAS/MAPK信号传导通路的激活与肺腺癌的发生、发展和转移密切相关,可作为评估肺腺癌进展的有价值的指标。

Objective To investigate the role of RAS/MAPK signal transduction pathway in the clinically biological behavior of lung adenocarcinoma and its correlation with the prognosis of patients with lung adenocarcinoma. Methods The expression of epidermal growth factor receptor （EGFR）, phosphorylation of signal transcription activation transducer 1 （pSTAT1） and phosphorylation of extracellular signal-regulated kinase 1/2 （pERK1/2） in 23 cases of lung adenocarcinoma tissues and 9 cases of nonneoplastic lung tissues were determined using immunohistochemical method. Results In the adenocarcinoma group, the overexpression rates of EGFR and pERK1/ 2 in lung adenocarcinoma tissues were 73.9%（17/23） and 65.2%（15/23）, respectively. The expression of pERK1/2 was positively correlated with pathological stages and lymph node metastasis （Х^2 = 12. 049 and 6. 626 ,both P d0.05）, but not with TNM stage. The expression rate of pSTAT1 in lung adenocarcinoma tissues was 30.4%, which was not significantly different from that in nonneoplastic lung tissues. Conclusion The activation of RAS / MAPK signal transduction pathway is closely related to the occurrence, progression and metastasis of lung adenocarcinoma. Proteins such as EGFR and pERK1/2 can be used as valuable indicators for evaluating the progress of lung adenocarcinoma.